News

Infusions of Epstein-Barr virus (EBV)–specific cytotoxic T lymphocytes from healthy donors led to high response rates and significant extensions in overall survival for patients with rituximab-refractory EBV–associated lymphoproliferative disorders.

Osteoarthritis (OA) patients may have an effective new treatment to look forward to following the development of self-donated fat cell therapy.

Gene therapy can provide transformative disease-modifying effects, with potentially lifelong clinical benefits after a single therapeutic administration. The most advanced retinal gene therapy program in the United States is in phase III study.

This oncology drug snapshot takes a look at axitinib (Inlyta) for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.

Stem cell therapy for multiple sclerosis is effective at 3-year follow up, according to research published in JAMA Neurology.

Low pre-surgery uptake of a labeled glucose analogue, a marker of metabolic activity, in the primary tumor of patients with stage I non-small cell lung cancer is associated with increased overall survival and a longer time before tumor recurrence, a study shows. Patients with high labeled glucose uptake may benefit from additional therapy following surgery.

A gene therapy treatment for men with hemophilia B proved effective, and the researchers involved in the study estimate it saved $2.5 million for the trial's patients.

The study, published in the Journal of Thoracic Oncology, found that patients treated with definitive concurrent chemotherapy and radiation therapy for stage 3 non-small cell lung cancer have longer overall survival when treated by highly experienced facilities, either academic or community cancer centers.

Inherited variants in an androgen transporter gene may determine the time to progression (TTP) for men with prostate cancer receiving androgen deprivation therapy (ADT).

Neither sunitinib nor sorafenib reduced disease recurrence in patients with locally advanced renal cell carcinoma (RCC) when these agents were given to patients as adjuvant therapy, according to the results of a new study.

Genetic testing in metastatic non-small cell lung cancer (NSCLC) patients and subsequent molecular biomarker guided therapy is societally cost-effective compared to a chemotherapy treatment approach without molecular testing.

Patients with multiple sclerosis who received stem cell therapy instead of treatment with mitoxantrone achieved better outcomes over a 4-year-period.

Scientists are testing alternative therapeutic approaches that may delay disease progression and even protect and regenerate neurons.

An investigational cancer immunotherapy known as MPDL3280A (anti-PDL1) is receiving a breakthrough therapy designation from the US Food and Drug Administration (FDA) for treating non-small cell lung cancer (NSCLC).

For his efforts to prove that gene therapy could one day provide lasting control of IOP in patients with glaucoma with known genetic defects, Andras M. Komáromy, PhD, DVM, was awarded the 2015 Shaffer Prize for Innovative Glaucoma Research.

The anti–PD-L1 agent MPDL3280A has received a breakthrough therapy designation from the FDA for PD-L1–positive non–small cell lung cancer that has progressed during or after platinum-based chemotherapy, as well as a targeted therapy for patients with EGFR- or ALK-positive tumors.

With 8 therapies approved by the US Food and Drug Administration (FDA) for the treatment of patients with advanced renal cell carcinoma (RCC), practitioners are faced with the challenge of selecting the most appropriate therapies for their patients within this crowded therapeutic landscape.

Wile several big and small pharmaceutical companies have invested research efforts in developing these complex, and expensive, treatment regimens, early results from trials indicate safety issues.

Amgen and Kite Pharma have announced that they will collaborate on the development of novel CAR T-cell immunotherapies, with Amgen providing cancer targets and Kite offering its engineered autologous cell therapy platform.

Treating patients with relapsing-remitting multiple sclerosis (RRMS) with autologous hematopoietic cell transplantation (HCT) has worked for most patients based on an interim report 3 years into a study. But the therapy has risks that critics say outweigh the benefits.

For children with Diamond-Blackfan Anemia (DBA) - an inherited condition defined by low red blood cell counts and limited progenitor cells in the bone marrow - growth hormone (GH) therapy was found to increase the short stature of patients - a symptom not widely analyzed.

The combination of (Cyramza) ramucirumab with docetaxel was today approved by the FDA for the treatment of advanced non-small cell lung cancer and in those who have been treated with platinum-based therapy.

In this video from the 2014 ASH Meeting, Dr. Grupp discusses data from a trial using CAR T-cell therapy in children and young adults with relapsed, treatment-resistant ALL.

Early consolidation therapy with brentuximab vedotin after autologous stem cell transplant improved progression-free survival of patients with Hodgkin lymphoma.

The anti-CD19 chimeric antigen receptor-modified T-cell therapy CTL019 demonstrated an impressive 92% complete response rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.

The top research being presented at the 2014 American Society of Hematology Annual Meeting will focus on immunotherapies and novel agents, according to Marcel R.M. van den Brink, MD, PhD.

The chimeric antigen receptor (CAR) T cell therapy JCAR015 has received a breakthrough therapy designation from the FDA as a treatment for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).

Up until now, these treatments have not produced promising efficacy results in clinical trials. MRI could show the way.